Thelansis

  Neuroleptic malignant syndrome (NMS) represents a life-threatening condition associated with the administration of dopamine-receptor antagonist medications or the abrupt cessation of dopaminergic agents. The primary instigator of NMS is the blockade of dopamine receptors, commonly induced by antipsychotic drugs. Despite its significance, the precise pathophysiology of NMS remains intricate and needs to be fully elucidated. Most NMS symptoms are attributed to a sudden decline in central dopaminergic activity resulting from either D2 receptor blockade or the abrupt withdrawal of D2 receptor stimulation. NMS constitutes a neurological emergency, wherein delays in diagnosis and intervention can precipitate substantial morbidity or mortality. The foremost intervention involves discontinuing the offending agent and implementing supportive measures. Supportive therapy encompasses aggressive cooling methods and rectifying fluid deficits and electrolyte imbalances. Patients are suscepti...